

# Helene Zephir

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9110193/publications.pdf>

Version: 2024-02-01

93  
papers

5,223  
citations

116194

36  
h-index

104191

69  
g-index

104  
all docs

104  
docs citations

104  
times ranked

5372  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuromyelitis Optica and Non-Organ-Specific Autoimmunity. Archives of Neurology, 2008, 65, 78-83.	4.9	497
2	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurology, The, 2017, 16, 976-986.	4.9	472
3	Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults. Neurology, 2018, 90, e1858-e1869.	1.5	401
4	Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. JAMA Neurology, 2020, 77, 1079.	4.5	357
5	Aquaporin-4 antibody-negative neuromyelitis optica. Neurology, 2013, 80, 2194-2200.	1.5	157
6	Acute Fulminant Demyelinating Disease. Archives of Neurology, 2007, 64, 1426.	4.9	148
7	Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Multiple Sclerosis Journal, 2011, 17, 1067-1073.	1.4	144
8	Switching From Natalizumab to Fingolimod in Multiple Sclerosis. JAMA Neurology, 2014, 71, 436.	4.5	133
9	Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Annals of Neurology, 2021, 89, 30-41.	2.8	123
10	Cognitive function in radiologically isolated syndrome. Multiple Sclerosis Journal, 2010, 16, 919-925.	1.4	116
11	Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. Journal of Neuroinflammation, 2019, 16, 134.	3.1	115
12	NMO-IgG and Devic's neuromyelitis optica: a French experience. Multiple Sclerosis Journal, 2008, 14, 440-445.	1.4	107
13	Cognitive Functions in Neuromyelitis Optica. Archives of Neurology, 2008, 65, 84-8.	4.9	98
14	Optical Coherence Tomography in Neuromyelitis Optica. Archives of Neurology, 2008, 65, 920-3.	4.9	96
15	Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2017, 23, 1377-1384.	1.4	89
16	Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset. Multiple Sclerosis Journal, 2014, 20, 1086-1094.	1.4	87
17	Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. Journal of Neurology, 2015, 262, 2329-2335.	1.8	86
18	DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. Annals of Clinical and Translational Neurology, 2021, 8, 1738-1744.	1.7	86

#	ARTICLE	IF	CITATIONS
19	Multiple sclerosis and depression: influence of interferon b therapy. <i>Multiple Sclerosis Journal</i> , 2003, 9, 284-288.	1.4	67
20	Evaluation of efficacy and tolerability of first-line therapies in NMOSD. <i>Neurology</i> , 2020, 94, e1645-e1656.	1.5	66
21	A comparative optical coherence tomography study in neuromyelitis optica spectrum disorder and multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1781-1793.	1.4	64
22	Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgGâ€Associated Disease and Neuromyelitis Optica Spectrum Disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	64
23	JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. <i>Multiple Sclerosis Journal</i> , 2014, 20, 822-829.	1.4	62
24	New insights into cell responses involved in experimental autoimmune encephalomyelitis and multiple sclerosis. <i>Immunology Letters</i> , 2005, 96, 11-26.	1.1	58
25	Adult-onset genetic leukoencephalopathies: A MRI pattern-based approach in a comprehensive study of 154 patients. <i>Brain</i> , 2015, 138, 284-292.	3.7	58
26	Altered B lymphocyte homeostasis and functions in systemic sclerosis. <i>Autoimmunity Reviews</i> , 2018, 17, 244-255.	2.5	58
27	Progress in understanding the pathophysiology of multiple sclerosis. <i>Revue Neurologique</i> , 2018, 174, 358-363.	0.6	56
28	A Benign Form of Neuromyelitis Optica. <i>Archives of Neurology</i> , 2011, 68, 918.	4.9	54
29	Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life. <i>Journal of Neurology</i> , 2015, 262, 1936-1945.	1.8	53
30	Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study. <i>PLoS ONE</i> , 2015, 10, e0132033.	1.1	48
31	Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders. <i>Revue Neurologique</i> , 2018, 174, 255-264.	0.6	47
32	Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. <i>Journal of Neurology</i> , 2019, 266, 806-815.	1.8	47
33	Comparison of Simoa <sup>TM</sup> and Ella <sup>TM</sup> to assess serum neurofilamentâ€light chain in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1141-1150.	1.7	45
34	Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion. <i>Multiple Sclerosis Journal</i> , 2010, 16, 87-92.	1.4	43
35	Long-term Follow-up of Acute Partial Transverse Myelitis. <i>Archives of Neurology</i> , 2012, 69, 357.	4.9	42
36	Optical Coherence Tomography in Clinically Isolated Syndrome. <i>Archives of Neurology</i> , 2009, 66, 1373-7.	4.9	37

#	ARTICLE	IF	CITATIONS
37	Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 936-944.	1.4	37
38	Asymptomatic optic nerve lesions. <i>Neurology</i> , 2020, 94, e2468-e2478.	1.5	37
39	Comparison of 3D double inversion recovery and 2D STIR FLAIR MR sequences for the imaging of optic neuritis: pilot study. <i>European Radiology</i> , 2014, 24, 3069-3075.	2.3	36
40	Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France. <i>JAMA Neurology</i> , 2020, 77, 94.	4.5	36
41	Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy. <i>Journal of Neurology</i> , 2012, 259, 2293-2298.	1.8	34
42	Optical coherence tomography: a window to the optic nerve in clinically isolated syndrome. <i>Brain</i> , 2019, 142, 903-915.	3.7	33
43	Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome. <i>JAMA Network Open</i> , 2021, 4, e2128271.	2.8	32
44	Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study. <i>Journal of Neuroinflammation</i> , 2022, 19, 62.	3.1	30
45	Managing MS in a changing treatment landscape. <i>Journal of Neurology</i> , 2011, 258, 728-739.	1.8	29
46	Proinflammatory B-cell profile in the early phases of MS predicts an active disease. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e431.	3.1	29
47	Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients. <i>Journal of Neurology</i> , 2018, 265, 2251-2259.	1.8	29
48	Optical coherence tomography for detection of asymptomatic optic nerve lesions in clinically isolated syndrome. <i>Neurology</i> , 2020, 95, e733-e744.	1.5	29
49	Immunopathogenesis and proposed clinical score for identifying Kelch-like protein-11 encephalitis. <i>Brain Communications</i> , 2021, 3, fcab185.	1.5	28
50	The long-term outcome of MOGAD: An observational national cohort study of 61 patients. <i>European Journal of Neurology</i> , 2021, 28, 1659-1664.	1.7	26
51	Diversified serum IgG response involving non-myelin CNS proteins during experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2006, 179, 53-64.	1.1	25
52	B-cell subsets up-regulate $\alpha 4$ integrin and accumulate in the cerebrospinal fluid in clinically isolated syndrome suggestive of multiple sclerosis onset. <i>Neuroscience Letters</i> , 2011, 487, 273-277.	1.0	25
53	Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis. <i>PLoS ONE</i> , 2017, 12, e0168834.	1.1	25
54	Diagnostic value of bright spotty lesions on MRI after a first episode of acute myelopathy. <i>Journal of Neuroradiology</i> , 2021, 48, 28-36.	0.6	24

#	ARTICLE	IF	CITATIONS
55	Length of optic nerve double inversion recovery hypersignal is associated with retinal axonal loss. <i>Multiple Sclerosis Journal</i> , 2016, 22, 649-658.	1.4	22
56	Changes in self-reactive IgG antibody repertoire after treatment of experimental autoimmune encephalomyelitis with anti-allergic drugs. <i>Journal of Neuroimmunology</i> , 2007, 182, 80-88.	1.1	21
57	Extensive myelitis associated with anti-NMDA receptor antibodies. <i>BMC Neurology</i> , 2013, 13, 211.	0.8	21
58	Milder multiple sclerosis course in patients with concomitant inflammatory bowel disease. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1135-1139.	1.4	20
59	A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 2025-2037.	1.7	20
60	Longitudinal Retinal Changes in <sc>MOGAD</sc>. <i>Annals of Neurology</i> , 2022, 92, 476-485.	2.8	20
61	Primed status of transitional B cells associated with their presence in the cerebrospinal fluid in early phases of multiple sclerosis. <i>Clinical Immunology</i> , 2011, 139, 12-20.	1.4	19
62	Mass Cytometry Identifies Expansion of T-bet+ B Cells and CD206+ Monocytes in Early Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2021, 12, 653577.	2.2	19
63	CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. <i>Neurology</i> , 2016, 87, 2491-2494.	1.5	18
64	Optic Nerve Lesion Length at the Acute Phase of Optic Neuritis Is Predictive of Retinal Neuronal Loss. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	16
65	Lumbar punctures: use and diagnostic efficiency in emergency medical departments. <i>International Journal of Emergency Medicine</i> , 2009, 2, 227-235.	0.6	15
66	High-affinity If1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis. <i>British Journal of Pharmacology</i> , 2015, 172, 1769-1782.	2.7	15
67	Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies. <i>Journal of Neuroinflammation</i> , 2020, 17, 128.	3.1	13
68	How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP). <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103076.	0.9	13
69	Optic nerve double inversion recovery hypersignal in patients with clinically isolated syndrome is associated with asymptomatic gadolinium-enhanced lesion. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1888-1895.	1.4	12
70	Should a psychotic or manic episode be considered an early manifestation of Multiple Sclerosis? A multiple case study. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 6, 93-96.	0.9	10
71	BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1556-1563.	1.4	9
72	Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort. <i>Multiple Sclerosis Journal</i> , 2021, 27, 729-741.	1.4	9

#	ARTICLE	IF	CITATIONS
73	Severe and rapidly evolving peripheral neuropathy revealing sporadic Creutzfeldt-Jakob disease. <i>Journal of Neurology</i> , 2009, 256, 134-136.	1.8	8
74	The effectiveness of natalizumab vs fingolimod – A comparison of international registry studies. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103012.	0.9	8
75	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. <i>CNS Drugs</i> , 2021, 35, 1217-1232.	2.7	8
76	A Spontaneous Model of Experimental Autoimmune Encephalomyelitis Provides Evidence of MOG-Specific B Cell Recruitment and Clonal Expansion. <i>Frontiers in Immunology</i> , 2022, 13, 755900.	2.2	8
77	Double-blind, randomized controlled trial of therapeutic plasma exchanges vs sham exchanges in moderate-to-severe relapses of multiple sclerosis. <i>Journal of Clinical Apheresis</i> , 2020, 35, 281-289.	0.7	7
78	Neurological Involvement in Childhood Evans Syndrome. <i>Journal of Clinical Immunology</i> , 2019, 39, 171-181.	2.0	6
79	Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal. <i>Neurotherapeutics</i> , 2022, 19, 476-490.	2.1	5
80	Continuous hemifacial myokymia as the revealing symptom of demyelinating disease of the CNS. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 11, 10-11.	0.9	4
81	Switching for convenience from first-line injectable treatments to oral treatments in multiple sclerosis: Data from a retrospective cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, 39-43.	0.9	4
82	Aquaporin 4 distribution in the brain and its relevance for the radiological appearance of neuromyelitis optica spectrum disease. <i>Journal of Neuroradiology</i> , 2021, 48, 170-175.	0.6	4
83	Fatal Enterovirus-related Myocarditis in a Patient with Devic's Syndrome Treated with Rituximab. <i>Cardiac Failure Review</i> , 2021, 7, e09.	1.2	4
84	Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 161-163.	0.9	3
85	Late-onset of Alpers-Huttenlocher syndrome: an unusual cause of refractory epilepsy and liver failure. <i>Acta Neurologica Belgica</i> , 2017, 117, 399-401.	0.5	3
86	Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1838-1851.	1.4	3
87	Autoimmune cerebellar ataxia with glutamic acid decarboxylase 65 antibodies associated with central vestibular symptoms. <i>Acta Neurologica Belgica</i> , 2017, 117, 775-776.	0.5	1
88	Thérapeutiques et prise en charge de la sclérose en plaques. , 2017, , 145-216.		1
89	Diagnostics différentiels de la sclérose en plaques. , 2017, , 113-143.		0
90	Signes et symptômes de la sclérose en plaques. , 2017, , 3-78.		0

#	ARTICLE	IF	CITATIONS
91	Sclérose en plaques: les nouvelles approches physiopathologiques. Pratique Neurologique - FMC, 2019, 10, 112-117.	0.1	0
92	Diagnostic positif de la sclérose en plaques. , 2017, , 79-111.		0
93	Author Response: Evaluation of Efficacy and Tolerability of First-Line Therapies in NMOSD. Neurology, 2021, 96, 295-296.	1.5	0